Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
August 06, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE)...
July 16, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
July 09, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
June 25, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including...
June 17, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
June 16, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate...
June 11, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

GLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing precision...
May 15, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
May 13, 2025 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...